As more people are surviving cancer, we must continue funding bold science

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Karen E. Knudsen, MBA, PhD
Chief executive officer, American Cancer Society, American Cancer Society Cancer Action Network
Table of Contents

YOU MAY BE INTERESTED IN

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated. 
Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
Karen E. Knudsen, MBA, PhD
Chief executive officer, American Cancer Society, American Cancer Society Cancer Action Network

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login